Gloschat CR, Koppel AC, Aras KK, et al. Arrhythmogenic and metabolic remodelling of failing human heart. J Physiol. 2016;594:3963 80. S7.7.1-17. Vakil K, Kazmirczak F, Sathnur N, et al. Implantable cardioverter- defibrillator use in patients with left ventricular assist devices: a sys- tematic review and meta-analysis. JACC Heart Fail. 2016;4:772 9. 7.7.2. HF With Preserved Ejection Fraction S7.7.2-1. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251 9. S7.7.2-2. Adabag S, Smith LG, Anand IS, et al. Sudden cardiac death in heart failure patients with preserved ejection fraction. J Card Fail. 2012;18:749 54. S7.7.2-3. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456 67. S7.7.2-4. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesar- tan in patients with chronic heart failure and preserved left- ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777 81. S7.7.2-5. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370: 1383 92. S7.7.2-6. Al-Khatib SM, Shaw LK, O Connor C, et al. Incidence and predictors of sudden cardiac death in patients with diastolic heart failure. J Cardiovasc Electrophysiol. 2007;18:1231 5. S7.7.2-7. Gatzoulis MA, Till JA, Somerville J, et al. Mechanoelectrical interac- tion in tetralogy of Fallot. QRS prolongation relates to right ventricu- lar size and predicts malignant ventricular arrhythmias and sudden death. Circulation. 1995;92:231 7. CLINICAL STATEMENTS AND GUIDELINES S7.7.2-8. Gatzoulis KA, Tsiachris D, Arsenos P, et al. Prognostic value of pro- grammed ventricular stimulation for sudden death in selected high risk patients with structural heart disease and preserved systolic function. Int J Cardiol. 2014;176:1449 51. 7.7.3. Left Ventricular Assist Device S7.7.3-1. 